Century Therapeutics, Inc. (IPSC)

Import this data to Google Sheets with:

=jivedata("IPSC","financials")

Full statements spill as a table. For one cell: =jivedata("IPSC","Revenue") or =jivedata("IPSC","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Century Therapeutics, Inc.

IPSC • CIK 0001850119

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$2,235	$6,589	$109,164	$109,164
Operating Income (Loss)	$-146,546	$-138,137	$-17,269	$-116,993
Interest Income, Other	—	$13,007	$7,346	$6,916
Other Nonoperating Income (Expense)	—	$354	$275	$215
Nonoperating Income (Expense)	$11,754	$13,361	$7,621	$7,131
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-134,792	$-124,776	$-9,648	$-9,648
Income Tax Expense (Benefit)	$1,881	$1,790	$-68	$-68
Net Income (Loss) Attributable to Parent	$-136,673	$-126,566	$-9,580	$-109,794
Weighted Average Number of Shares Outstanding, Basic	59,314,389	78,648,958	86,556,515	200,086,802
Weighted Average Number of Shares Outstanding, Diluted	57,755,842	78,648,958	86,556,515	200,009,371
Research and Development Expense (Excluding Acquired in Process Cost)	$92,710	$107,244	$95,667	$78,928
General and Administrative Expense	$34,706	$33,155	$24,003	$20,157
Impairment of Long-Lived Assets to be Disposed of	—	—	$6,763	$6,763
Goodwill, Impairment Loss	—	$4,327	$4,327	$4,327
Operating Expenses	$148,781	$144,726	$126,433	$116,993
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax	$2,602	$153	$-294	$-777
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	$-32	$63	$63	$63
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-134,103	$-126,350	$-9,874	$-110,571

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$47,324	$58,441	$61,853	$49,642
Short-term Investments	$125,414	$130,851	$55,261	$70,070
Property, Plant and Equipment, Net	$71,705	$62,141	$50,026	$34,482
Prepaid Expense and Other Assets, Current	$4,256	$4,759	$3,655	$5,056
Operating Lease, Right-of-Use Asset	$20,376	$28,706	$16,139	$13,513
Assets, Current	$176,994	$194,051	$120,769	$124,768
Restricted Cash, Noncurrent	$1,979	$2,772	$2,359	$2,359
Long-term Investments	$89,096	$30,818	$30,818	$77,477
Intangible Assets, Net (Excluding Goodwill)	—	$34,200	$34,200	$34,200
Deposits Assets, Noncurrent	$541	$528	$211	$207
Assets	$360,691	$353,216	$223,704	$287,006
Operating Lease, Liability, Noncurrent	$46,658	$48,960	$40,241	$34,626
Business Combination, Contingent Consideration, Liability, Noncurrent	—	$8,738	$8,738	$784
Deferred Income Tax Liabilities, Net	$10,388	$4,374	$4,301	$4,301
Liabilities	$175,941	$191,854	$64,768	$54,661
Common Stock, Value, Issued	$6	$9	$9	$18
Additional Paid in Capital, Common Stock	$840,407	$943,366	$950,814	$1,081,133
Retained Earnings (Accumulated Deficit)	$-655,771	$-782,337	$-791,917	$-848,112
Accumulated Other Comprehensive Income (Loss), Net of Tax	$108	$324	$30	$-694
Stockholders' Equity Attributable to Parent	$184,750	$161,362	$158,936	$232,345
Accounts Payable, Current	$2,741	$3,075	$4,773	$4,823
Business Combination, Contingent Consideration, Liability, Current	—	—	$3,757	$1,939
Deposit Liability, Current	$584	$82	$20	$20
Deferred Revenue, Current	$4,372	$109,164	$109,164	$109,164
Liabilities, Current	$17,846	$129,782	$20,226	$15,068
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	125,236,190	300,000,000	300,000,000	300,000,000
Common Stock, Shares, Issued	60,335,701	85,836,429	87,519,096	180,547,456

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-136,673	$-126,566	$-9,580	$-109,794
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	$-36,941	$11,910	$3,798	$-7,586
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$49,303	$61,213	$65,011	$64,128
Depreciation	$13,044	$13,304	$13,101	$12,298
Payments to Acquire Property, Plant, and Equipment	$13,736	$154	$848	$1,334
Payments to Acquire Debt Securities, Available-for-sale	$209,034	$119,548	$51,174	$183,280
Share-based Payment Arrangement, Noncash Expense	$14,622	$12,688	$6,840	$5,587
Proceeds from Sale of Debt Securities, Available-for-sale	$283,902	$176,792	$159,523	$136,739
Asset Impairment Charges	$16,365	$16,365	$6,763	$6,763
Payments to Acquire Additional Interest in Subsidiaries	—	$9,608	$9,608	$9,608
Accretion (Amortization) of Discounts and Premiums, Investments	$3,984	$4,812	$2,357	$1,215
Net Cash Provided by (Used in) Investing Activities	$61,132	$47,482	$107,501	$-47,816
Gain (Loss) on Termination of Lease	—	—	$1,395	—
Deferred Income Tax Expense (Benefit)	$-3	$869	$-73	$-73
Increase (Decrease) in Prepaid Expense and Other Assets	$-667	$-543	$-2,342	$-689
Proceeds from Issuance of Common Stock	$516	$141	$173	$602
IncreaseDecreaseInOperatingLeaseLiability	$13,819	$-3,365	$-4,978	$-4,406
Increase (Decrease) in Deferred Revenue	$-2,235	$-6,589	$-109,164	$-109,164
Increase (Decrease) in Accounts Payable	$-2,361	$-1,469	$1,562	$1,614
Net Cash Provided by (Used in) Financing Activities	$-9,725	$74,563	$173	$126,987
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	$-730	$1,602	$-4,315	$-1,276
Net Cash Provided by (Used in) Operating Activities	$-88,348	$-110,135	$-103,876	$-86,757
Income Taxes Paid	$2,521	$501	$3,892	$3,892

Jive Data

Google Sheets add-onSheets Account

Import this data to Google Sheets with:

=jivedata("IPSC","financials")

Full statements spill as a table. For one cell: =jivedata("IPSC","Revenue") or =jivedata("IPSC","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Century Therapeutics, Inc.

IPSC • CIK 0001850119

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$2,235	$6,589	$109,164	$109,164
Operating Income (Loss)	$-146,546	$-138,137	$-17,269	$-116,993
Interest Income, Other	—	$13,007	$7,346	$6,916
Other Nonoperating Income (Expense)	—	$354	$275	$215
Nonoperating Income (Expense)	$11,754	$13,361	$7,621	$7,131
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-134,792	$-124,776	$-9,648	$-9,648
Income Tax Expense (Benefit)	$1,881	$1,790	$-68	$-68
Net Income (Loss) Attributable to Parent	$-136,673	$-126,566	$-9,580	$-109,794
Weighted Average Number of Shares Outstanding, Basic	59,314,389	78,648,958	86,556,515	200,086,802
Weighted Average Number of Shares Outstanding, Diluted	57,755,842	78,648,958	86,556,515	200,009,371
Research and Development Expense (Excluding Acquired in Process Cost)	$92,710	$107,244	$95,667	$78,928
General and Administrative Expense	$34,706	$33,155	$24,003	$20,157
Impairment of Long-Lived Assets to be Disposed of	—	—	$6,763	$6,763
Goodwill, Impairment Loss	—	$4,327	$4,327	$4,327
Operating Expenses	$148,781	$144,726	$126,433	$116,993
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax	$2,602	$153	$-294	$-777
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	$-32	$63	$63	$63
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-134,103	$-126,350	$-9,874	$-110,571

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$47,324	$58,441	$61,853	$49,642
Short-term Investments	$125,414	$130,851	$55,261	$70,070
Property, Plant and Equipment, Net	$71,705	$62,141	$50,026	$34,482
Prepaid Expense and Other Assets, Current	$4,256	$4,759	$3,655	$5,056
Operating Lease, Right-of-Use Asset	$20,376	$28,706	$16,139	$13,513
Assets, Current	$176,994	$194,051	$120,769	$124,768
Restricted Cash, Noncurrent	$1,979	$2,772	$2,359	$2,359
Long-term Investments	$89,096	$30,818	$30,818	$77,477
Intangible Assets, Net (Excluding Goodwill)	—	$34,200	$34,200	$34,200
Deposits Assets, Noncurrent	$541	$528	$211	$207
Assets	$360,691	$353,216	$223,704	$287,006
Operating Lease, Liability, Noncurrent	$46,658	$48,960	$40,241	$34,626
Business Combination, Contingent Consideration, Liability, Noncurrent	—	$8,738	$8,738	$784
Deferred Income Tax Liabilities, Net	$10,388	$4,374	$4,301	$4,301
Liabilities	$175,941	$191,854	$64,768	$54,661
Common Stock, Value, Issued	$6	$9	$9	$18
Additional Paid in Capital, Common Stock	$840,407	$943,366	$950,814	$1,081,133
Retained Earnings (Accumulated Deficit)	$-655,771	$-782,337	$-791,917	$-848,112
Accumulated Other Comprehensive Income (Loss), Net of Tax	$108	$324	$30	$-694
Stockholders' Equity Attributable to Parent	$184,750	$161,362	$158,936	$232,345
Accounts Payable, Current	$2,741	$3,075	$4,773	$4,823
Business Combination, Contingent Consideration, Liability, Current	—	—	$3,757	$1,939
Deposit Liability, Current	$584	$82	$20	$20
Deferred Revenue, Current	$4,372	$109,164	$109,164	$109,164
Liabilities, Current	$17,846	$129,782	$20,226	$15,068
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	125,236,190	300,000,000	300,000,000	300,000,000
Common Stock, Shares, Issued	60,335,701	85,836,429	87,519,096	180,547,456

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-136,673	$-126,566	$-9,580	$-109,794
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	$-36,941	$11,910	$3,798	$-7,586
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$49,303	$61,213	$65,011	$64,128
Depreciation	$13,044	$13,304	$13,101	$12,298
Payments to Acquire Property, Plant, and Equipment	$13,736	$154	$848	$1,334
Payments to Acquire Debt Securities, Available-for-sale	$209,034	$119,548	$51,174	$183,280
Share-based Payment Arrangement, Noncash Expense	$14,622	$12,688	$6,840	$5,587
Proceeds from Sale of Debt Securities, Available-for-sale	$283,902	$176,792	$159,523	$136,739
Asset Impairment Charges	$16,365	$16,365	$6,763	$6,763
Payments to Acquire Additional Interest in Subsidiaries	—	$9,608	$9,608	$9,608
Accretion (Amortization) of Discounts and Premiums, Investments	$3,984	$4,812	$2,357	$1,215
Net Cash Provided by (Used in) Investing Activities	$61,132	$47,482	$107,501	$-47,816
Gain (Loss) on Termination of Lease	—	—	$1,395	—
Deferred Income Tax Expense (Benefit)	$-3	$869	$-73	$-73
Increase (Decrease) in Prepaid Expense and Other Assets	$-667	$-543	$-2,342	$-689
Proceeds from Issuance of Common Stock	$516	$141	$173	$602
IncreaseDecreaseInOperatingLeaseLiability	$13,819	$-3,365	$-4,978	$-4,406
Increase (Decrease) in Deferred Revenue	$-2,235	$-6,589	$-109,164	$-109,164
Increase (Decrease) in Accounts Payable	$-2,361	$-1,469	$1,562	$1,614
Net Cash Provided by (Used in) Financing Activities	$-9,725	$74,563	$173	$126,987
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	$-730	$1,602	$-4,315	$-1,276
Net Cash Provided by (Used in) Operating Activities	$-88,348	$-110,135	$-103,876	$-86,757
Income Taxes Paid	$2,521	$501	$3,892	$3,892

Century Therapeutics, Inc.

Statement Consolidated Statements of Operations and Comprehensive Loss

Statement Consolidated Balance Sheets

Statement Consolidated Statements of Cash Flows

Century Therapeutics, Inc.

Statement Consolidated Statements of Operations and Comprehensive Loss

Statement Consolidated Balance Sheets

Statement Consolidated Statements of Cash Flows